Trials / Withdrawn
WithdrawnNCT03603990
Effect of Vitrectomy on the Evolution of Refractory Diabetic Macular Edema
Effect of Vitrectomy on the Evolution of Refractory Diabetic Macular Edema: a Randomized Pragmatic Controlled Study
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild · Network
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
For patients with at least one eye with non-tractional diabetic edema refractory to 6 months of anti-VEGF injections (anti Vascular endothelial growth factor injections), a randomization is done: one group of patients will receive the standard treatment (anti-VEGF injections, switch to another anti-VEGF drug, additional photocoagulation or any other treatment except vitrectomy during the first 6 months after the randomisation) and the other group of patients will receive vitrectomy (with only additional photocoagulation during the first 6 months, then any treatment from 6 months after the randomization).
Detailed description
In case both eyes present refractory diabetic macular edema (DME) and are eligible, the eye with the worst DME will be included and randomized.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Vitrectomy | During the first 6 month :Only Panretinal photocoagulation(if high-risk PDR or rubeosis iridis) may be given. After First Six Months : All therapies for DME may be given at the discretion of the investigator |
| PROCEDURE | Usual care | Patients with usual care according to the investigator choice : During the first 6 month : All therapies for DME may be given at the discretion of the investigator during the study, except a vitrectomy. After First Six Months : All therapies for DME may be given at the discretion of the investigator, including a vitrectomy. |
Timeline
- Start date
- 2018-09-01
- Primary completion
- 2020-03-01
- Completion
- 2020-03-01
- First posted
- 2018-07-27
- Last updated
- 2020-05-14
Source: ClinicalTrials.gov record NCT03603990. Inclusion in this directory is not an endorsement.